Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNK3 | O14649 | 2/20 | 0.32 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.31 |
| ▸ | PTPN5 | P54829 | 3/20 | 0.31 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.31 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.30 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.30 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7397958 | 0.88 | MLNR (0.32) | KCNK3 | |
| SCHEMBL7438915 | 0.88 | GRM4 (0.30) | — | |
| SCHEMBL7403425 | 0.87 | PTPN1 (0.34) | KCNK3PTPN1PTPN5HSPD1HSPE1 | |
| SCHEMBL7395277 | 0.86 | HTR6 (0.35) | — | |
| SCHEMBL7398223 | 0.86 | MLNR (0.32) | PIK3C2GPIK3CAPIK3CG | |
| SCHEMBL7404517 | 0.86 | — | — | |
| SCHEMBL7404566 | 0.86 | TRIM24 (0.39) | PIK3CG | |
| SCHEMBL7405946 | 0.85 | MMP2 (0.32) | — | |
| SCHEMBL7405439 | 0.85 | PIK3C2G (0.30) | PIK3C2GPIK3CAPIK3CG | |
| SCHEMBL7405226 | 0.85 | CBLB (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246125-A1 | PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE | 712 NORTH INC. | 2021-08-12 | — | — | US | claimed |
| US-6169181-B1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2001-01-02 | — | — | US | claimed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | claimed |
| US-6169181-B1 | HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITORS | PHARMACIA & UPJOHN COMPANY | 2001-01-02 | — | — | US | disclosed |
| US-5852195-A | Pyranone compounds useful to treat retroviral infections | PHARMACIA & UPJOHN COMPANY (US) | 1998-12-22 | — | — | US | disclosed |
| EP-0758327-A1 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1997-02-19 | — | — | EP | disclosed |
| WO-1995030670-A2 | PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS | PHARMACIA & UPJOHN COMPANY (US) | 1995-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246125-A1 | PYRANONE COMPOUNDS USEFUL TO MODULATE OMA1 PROTEASE | OPA1, OLA1, PITRM1 | KCNK3 899/4885PTPN1 3182/4885PTPN5 4187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.